EcoDrugPlus

Histone Deacetylase 3

Ensembl ID : ENSVVUG00000019813
Gene Symbol: HDAC3
3 Cross references
156 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSVVUG00000023028
Gene Symbol: HDAC4
3 Cross references
263 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSVVUG00000017591
Gene Symbol: HDAC5
3 Cross references
194 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSVVUG00000017760
Gene Symbol: HDAC6
3 Cross references
183 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSVVUG00000018010
Gene Symbol: HDAC7
3 Cross references
260 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSVVUG00000025508
Gene Symbol: HDAC8
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 9

Ensembl ID : ENSVVUG00000008429
Gene Symbol: HDAC9
3 Cross references
234 Possible Orthologues:

Hydroxysteroid 11-Beta Dehydrogenase 1

Ensembl ID : ENSVVUG00000009432
Gene Symbol: HSD11B1
3 Cross references
248 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSVVUG00000018438
Gene Symbol: HCN4
3 Cross references
287 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSVVUG00000014694
Gene Symbol: HCRTR1
3 Cross references
96 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSVVUG00000001234
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSVVUG00000020390
Gene Symbol: IDO1
3 Cross references
98 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).